Observational studyPain research & management2026
Prevalence and Clinical Phenotypes of Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: The MOGHEAD Study.
Observational study in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07479212 (Single-center Ambispective Observational Study to Evaluate the Prevalence and Phenotype of Headache in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-center Ambispective Observational Study to Evaluate the Prevalence and Phenotype of Headache in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGHEAD).
Who cites it
1 citing paper in PubMed.
- Prevalence and Clinical Phenotypes of Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: The MOGHEAD Study.Pain research & management · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHeadache associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is poorly characterized.
objectiveTo investigate the prevalence, clinical phenotypes, and longitudinal evolution of headache in MOGAD.
methodsIn this single-center retrospective cohort study based on prospectively collected clinical data, consecutive adult patients diagnosed with MOGAD between 2020 and 2024 were enrolled. Demographic, clinical, and radiological data were collected. Headaches were classified according to the International Classification of Headache Disorders. Patients underwent quarterly evaluations over 1 year. Pain severity was assessed using the Numeric Rating Scale at baseline and at the 1-year visit, while headache-related disability was assessed using the Migraine Disability Assessment at the 1-year visit in patients reporting headache.
resultsTwenty-two patients were included (median age 35 years; 54.5% male). Headache occurred in 54.5% at onset and 68.2% after 1 year. Pre-existing primary headache disorders were present in 54.5%. Headaches showed heterogeneous features, commonly retro-orbital or unilateral frontal pain with pulsating or pressure-like quality and associated photophobia/phonophobia. Migraine was the predominant phenotype at 1 year. Headache characteristics evolved over time in 73.7% of the cases, while 50% reported inadequate response to symptomatic therapy. Female sex, pre-existing headache, and rituximab exposure were associated with headache persistence in univariable analyses.
conclusionsHeadache is common in MOGAD, often pre-existing, with heterogeneous phenotypes, although its clinical burden and evolution over time remain incompletely characterized. New-onset retro-orbital headache may represent a clinical red flag requiring further investigation.
trial registrationClinicalTrials.gov identifier: NCT07479212.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.